Past Papers · SAQ
Anticoagulants — Heparin vs Enoxaparin
2025B Q20
Exam questionDescribe the following pharmacology of both unfractionated heparin and bivalirudin: (a) indications for use (10% of marks) (b) mechanism of action (30% of marks) (c) monitoring and reversal (10% of marks) (d) important pharmacokinetic differences and considerations when using in the intensive care unit (ICU) (30% of marks) (e) adverse effects (20% of marks).
CICMWrecks answer
Master answer
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
UNFRACTIONATED HEPARIN (UFH)
Haematology · Haematology · Level 1
|
LOW MOLECULAR WEIGHT HEPARIN (LMWH)
Haematology · Haematology · Level 1
|
|---|---|---|
| Mechanism of action | Activates antithrombin which then inhibits clotting factors thrombin and factor Xa |
Activates antithrombin but due to shorter length preferentially inhibits factor Xa |
| Absorption | reduced due to endothelial binding (SC), IV |
up to 90% via SC (greater than heparin) |
| Protein binding | very high protein binding. |
less prot bind than heparin |
| Volume of distribution | Vd 0.05-0.1L/kg |
Vd ~ 0.1L/kg |
| Metabolism | By heparinases in the liver, |
Hepatic depolymerisation and desulfation to less active fragments |
| Excretion | urine as inactive metabolites, little change in renal failure |
urine as 40% of dose and 10% active fragments, dose adjustment in renal failure |
| Half-life | variable half life due to protein binding 30 - 150 mins depending on dose |
2-4 times longer half-life than heparin |
| Adverse Effects Toxicity | Bleeding, Heparin Induced Thrombocytopaenia, Osteoporosis, |
Bleeding |
| Class Group | Anticoagulants |
Anticoagulants |
| Indications Uses | 1. the prevention of venous thromboembolic disease |
1. the prevention of venous thromboembolic disease |
| Introduction | Heparin is an anioic, mucopolysaccaride, MW: 5000-25000 Daltons |
Enoxaparin is a LMWH prepared from |
| Legacy Cicm Level | Level 1 |
Level 1 |
| Presentation | s/c or i.v. - I.U. (not mg) due to variable potencies. 5000IU BD s/c or 5000IU IV then infusion-rate based on wttitrated (APTT) |
Usually s/c, but can be given i.v. Monitor: |
| Special Points | Reversal: |
Reversal: |
Past papers
Exam appearances
| Exam | Exact exam wording | Candidate success |
|---|---|---|
| 2025B Q20 | Describe the following pharmacology of both unfractionated heparin and bivalirudin: (a) indications for use (10% of marks) (b) mechanism of action (30% of marks) (c) monitoring and reversal (10% of marks) (d) important pharmacokinetic differences and considerations when using in the intensive care unit (ICU) (30% of marks) (e) adverse effects (20% of marks). | 35% |
| 2024A Q20 | Outline the important similarities and differences between unfractionated heparin and enoxaparin using the following headings (20% of marks each): (i) Mechanism of action (ii) Pharmacokinetics (iii) Adverse effects (iv) Dosing (v) Monitoring and reversal | 27% |
| 2018B Q20 | Describe the pharmacology of heparin highlighting important differences between unfractionated and fractionated (low molecular weight) heparin. | 71% |
| 2017B Q05 | Compare and contrast unfractionated heparin with low molecular weight heparin | 68% |
| 2009B Q20 | Compare and contrast the pharmacology of heparin and enoxaparin. | 89% |